 | • レポートコード：MRC2Q12-18860 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、弱毒化ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 弱毒化ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 弱毒化ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 弱毒化ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの弱毒化ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の弱毒化ワクチンの売上および2028年までの予測に焦点を当てています。 弱毒化ワクチンのグローバル主要企業には、Merck & Co.、GlaxoSmithKline plc、Pfizer Inc、Sanofi、Astellas Pharma、Johnson & Johnson、CSL Limited、Serum Institute of India Pvt. Ltd.、Biken、Green Cross Corporation、Shanghai Rongsheng Biotech、Changchun BCHT Biotechnology Co.,Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 弱毒化ワクチン市場は、タイプとアプリケーションによって区分されます。世界の弱毒化ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 細菌ワクチン、ウイルスワクチン 【アプリケーション別セグメント】 病院、診療所、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 弱毒化ワクチン製品概要 - タイプ別市場（細菌ワクチン、ウイルスワクチン） - アプリケーション別市場（病院、診療所、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の弱毒化ワクチン販売量予測2017-2028 - 世界の弱毒化ワクチン売上予測2017-2028 - 弱毒化ワクチンの地域別販売量 - 弱毒化ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別弱毒化ワクチン販売量 - 主要メーカー別弱毒化ワクチン売上 - 主要メーカー別弱毒化ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（細菌ワクチン、ウイルスワクチン） - 弱毒化ワクチンのタイプ別販売量 - 弱毒化ワクチンのタイプ別売上 - 弱毒化ワクチンのタイプ別価格 ・アプリケーション別市場規模（病院、診療所、その他） - 弱毒化ワクチンのアプリケーション別販売量 - 弱毒化ワクチンのアプリケーション別売上 - 弱毒化ワクチンのアプリケーション別価格 ・北米市場 - 北米の弱毒化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の弱毒化ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの弱毒化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の弱毒化ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の弱毒化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の弱毒化ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の弱毒化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の弱毒化ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの弱毒化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の弱毒化ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Merck & Co.、GlaxoSmithKline plc、Pfizer Inc、Sanofi、Astellas Pharma、Johnson & Johnson、CSL Limited、Serum Institute of India Pvt. Ltd.、Biken、Green Cross Corporation、Shanghai Rongsheng Biotech、Changchun BCHT Biotechnology Co.,Ltd ・産業チェーン及び販売チャネル分析 - 弱毒化ワクチンの産業チェーン分析 - 弱毒化ワクチンの原材料 - 弱毒化ワクチンの生産プロセス - 弱毒化ワクチンの販売及びマーケティング - 弱毒化ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 弱毒化ワクチンの産業動向 - 弱毒化ワクチンのマーケットドライバー - 弱毒化ワクチンの課題 - 弱毒化ワクチンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Attenuated Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Attenuated Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Attenuated Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Attenuated Vaccine include Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd. and Biken, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Attenuated Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Attenuated Vaccine market. Further, it explains the major drivers and regional dynamics of the global Attenuated Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Merck & Co.
GlaxoSmithKline plc
Pfizer Inc
Sanofi
Astellas Pharma
Johnson & Johnson
CSL Limited
Serum Institute of India Pvt. Ltd.
Biken
Green Cross Corporation
Shanghai Rongsheng Biotech
Changchun BCHT Biotechnology Co.,Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Attenuated Vaccine Segment by Type
Bacterial Vaccine
Viral Vaccine
Attenuated Vaccine Segment by Application
Hospital
Clinic
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Attenuated Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Attenuated Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Attenuated Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Attenuated Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Attenuated Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Attenuated Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Attenuated Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd. and Biken, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Attenuated Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Attenuated Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Attenuated Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Attenuated Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Bacterial Vaccine
1.2.3 Viral Vaccine
1.3 Market by Application
1.3.1 Global Attenuated Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Attenuated Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Attenuated Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Attenuated Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Attenuated Vaccine Sales by Region
2.4.1 Global Attenuated Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Attenuated Vaccine by Region (2023-2028)
2.5 Global Attenuated Vaccine Revenue by Region
2.5.1 Global Attenuated Vaccine Revenue by Region (2017-2022)
2.5.2 Global Attenuated Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Attenuated Vaccine Sales by Manufacturers
3.1.1 Global Top Attenuated Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Attenuated Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Attenuated Vaccine in 2021
3.2 Global Attenuated Vaccine Revenue by Manufacturers
3.2.1 Global Attenuated Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Attenuated Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Attenuated Vaccine Revenue in 2021
3.3 Global Attenuated Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Attenuated Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Attenuated Vaccine Sales by Type
4.1.1 Global Attenuated Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Attenuated Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Attenuated Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Attenuated Vaccine Revenue by Type
4.2.1 Global Attenuated Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Attenuated Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Attenuated Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Attenuated Vaccine Price by Type
4.3.1 Global Attenuated Vaccine Price by Type (2017-2022)
4.3.2 Global Attenuated Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Attenuated Vaccine Sales by Application
5.1.1 Global Attenuated Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Attenuated Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Attenuated Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Attenuated Vaccine Revenue by Application
5.2.1 Global Attenuated Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Attenuated Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Attenuated Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Attenuated Vaccine Price by Application
5.3.1 Global Attenuated Vaccine Price by Application (2017-2022)
5.3.2 Global Attenuated Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Attenuated Vaccine Market Size by Type
6.1.1 North America Attenuated Vaccine Sales by Type (2017-2028)
6.1.2 North America Attenuated Vaccine Revenue by Type (2017-2028)
6.2 North America Attenuated Vaccine Market Size by Application
6.2.1 North America Attenuated Vaccine Sales by Application (2017-2028)
6.2.2 North America Attenuated Vaccine Revenue by Application (2017-2028)
6.3 North America Attenuated Vaccine Market Size by Country
6.3.1 North America Attenuated Vaccine Sales by Country (2017-2028)
6.3.2 North America Attenuated Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Attenuated Vaccine Market Size by Type
7.1.1 Europe Attenuated Vaccine Sales by Type (2017-2028)
7.1.2 Europe Attenuated Vaccine Revenue by Type (2017-2028)
7.2 Europe Attenuated Vaccine Market Size by Application
7.2.1 Europe Attenuated Vaccine Sales by Application (2017-2028)
7.2.2 Europe Attenuated Vaccine Revenue by Application (2017-2028)
7.3 Europe Attenuated Vaccine Market Size by Country
7.3.1 Europe Attenuated Vaccine Sales by Country (2017-2028)
7.3.2 Europe Attenuated Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Attenuated Vaccine Market Size by Type
8.1.1 Asia Pacific Attenuated Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Attenuated Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Attenuated Vaccine Market Size by Application
8.2.1 Asia Pacific Attenuated Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Attenuated Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Attenuated Vaccine Market Size by Region
8.3.1 Asia Pacific Attenuated Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Attenuated Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Attenuated Vaccine Market Size by Type
9.1.1 Latin America Attenuated Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Attenuated Vaccine Revenue by Type (2017-2028)
9.2 Latin America Attenuated Vaccine Market Size by Application
9.2.1 Latin America Attenuated Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Attenuated Vaccine Revenue by Application (2017-2028)
9.3 Latin America Attenuated Vaccine Market Size by Country
9.3.1 Latin America Attenuated Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Attenuated Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Attenuated Vaccine Market Size by Type
10.1.1 Middle East and Africa Attenuated Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Attenuated Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Attenuated Vaccine Market Size by Application
10.2.1 Middle East and Africa Attenuated Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Attenuated Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Attenuated Vaccine Market Size by Country
10.3.1 Middle East and Africa Attenuated Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Attenuated Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck & Co.
11.1.1 Merck & Co. Corporation Information
11.1.2 Merck & Co. Overview
11.1.3 Merck & Co. Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck & Co. Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck & Co. Recent Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Overview
11.2.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline plc Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline plc Recent Developments
11.3 Pfizer Inc
11.3.1 Pfizer Inc Corporation Information
11.3.2 Pfizer Inc Overview
11.3.3 Pfizer Inc Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Pfizer Inc Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Inc Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sanofi Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 Astellas Pharma
11.5.1 Astellas Pharma Corporation Information
11.5.2 Astellas Pharma Overview
11.5.3 Astellas Pharma Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Astellas Pharma Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Astellas Pharma Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Overview
11.6.3 Johnson & Johnson Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Johnson & Johnson Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Johnson & Johnson Recent Developments
11.7 CSL Limited
11.7.1 CSL Limited Corporation Information
11.7.2 CSL Limited Overview
11.7.3 CSL Limited Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 CSL Limited Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 CSL Limited Recent Developments
11.8 Serum Institute of India Pvt. Ltd.
11.8.1 Serum Institute of India Pvt. Ltd. Corporation Information
11.8.2 Serum Institute of India Pvt. Ltd. Overview
11.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Serum Institute of India Pvt. Ltd. Recent Developments
11.9 Biken
11.9.1 Biken Corporation Information
11.9.2 Biken Overview
11.9.3 Biken Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Biken Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Biken Recent Developments
11.10 Green Cross Corporation
11.10.1 Green Cross Corporation Corporation Information
11.10.2 Green Cross Corporation Overview
11.10.3 Green Cross Corporation Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Green Cross Corporation Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Green Cross Corporation Recent Developments
11.11 Shanghai Rongsheng Biotech
11.11.1 Shanghai Rongsheng Biotech Corporation Information
11.11.2 Shanghai Rongsheng Biotech Overview
11.11.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Shanghai Rongsheng Biotech Recent Developments
11.12 Changchun BCHT Biotechnology Co.,Ltd
11.12.1 Changchun BCHT Biotechnology Co.,Ltd Corporation Information
11.12.2 Changchun BCHT Biotechnology Co.,Ltd Overview
11.12.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Attenuated Vaccine Industry Chain Analysis
12.2 Attenuated Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Attenuated Vaccine Production Mode & Process
12.4 Attenuated Vaccine Sales and Marketing
12.4.1 Attenuated Vaccine Sales Channels
12.4.2 Attenuated Vaccine Distributors
12.5 Attenuated Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Attenuated Vaccine Industry Trends
13.2 Attenuated Vaccine Market Drivers
13.3 Attenuated Vaccine Market Challenges
13.4 Attenuated Vaccine Market Restraints
14 Key Findings in The Global Attenuated Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer